Commensal consortia decolonize Enterobacteriaceae via ecological control.

Autor: Furuichi M; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan., Kawaguchi T; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan., Pust MM; Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Center for Computational and Integrative Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Yasuma-Mitobe K; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan., Plichta DR; Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hasegawa N; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan., Ohya T; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan., Bhattarai SK; Department of Microbiology and Physiological Systems, Program in Microbiome Dynamics, UMass Chan Medical School, Worcester, MA, USA., Sasajima S; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan., Aoto Y; JSR-Keio University Medical and Chemical Innovation Center, Keio University School of Medicine, Tokyo, Japan., Tuganbaev T; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.; Human Biology Microbiome Quantum Research Center (Bio2Q), Keio University, Tokyo, Japan., Yaginuma M; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan., Ueda M; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.; JSR-Keio University Medical and Chemical Innovation Center, Keio University School of Medicine, Tokyo, Japan., Okahashi N; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.; Department of Bioinformatic Engineering, Graduate School of Information Science and Technology, Osaka University, Osaka, Japan.; Division of Physiological Chemistry and Metabolism, Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Amafuji K; JSR-Keio University Medical and Chemical Innovation Center, Keio University School of Medicine, Tokyo, Japan., Kiridoshi Y; JSR-Keio University Medical and Chemical Innovation Center, Keio University School of Medicine, Tokyo, Japan., Sugita K; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan., Stražar M; Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Avila-Pacheco J; Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Pierce K; Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Clish CB; Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Skelly AN; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan., Hattori M; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.; Cooperative Major in Advanced Health Science, Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan., Nakamoto N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Caballero S; Vedanta Biosciences, Cambridge, MA, USA., Norman JM; Vedanta Biosciences, Cambridge, MA, USA., Olle B; Vedanta Biosciences, Cambridge, MA, USA., Tanoue T; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan., Suda W; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.; Cooperative Major in Advanced Health Science, Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan., Arita M; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.; Human Biology Microbiome Quantum Research Center (Bio2Q), Keio University, Tokyo, Japan.; Division of Physiological Chemistry and Metabolism, Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Bucci V; Department of Microbiology and Physiological Systems, Program in Microbiome Dynamics, UMass Chan Medical School, Worcester, MA, USA., Atarashi K; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.; Human Biology Microbiome Quantum Research Center (Bio2Q), Keio University, Tokyo, Japan., Xavier RJ; Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. xavier@molbio.mgh.harvard.edu.; Center for Computational and Integrative Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. xavier@molbio.mgh.harvard.edu.; Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA. xavier@molbio.mgh.harvard.edu., Honda K; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. kenya@keio.jp.; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. kenya@keio.jp.; Human Biology Microbiome Quantum Research Center (Bio2Q), Keio University, Tokyo, Japan. kenya@keio.jp.
Jazyk: angličtina
Zdroj: Nature [Nature] 2024 Sep; Vol. 633 (8031), pp. 878-886. Date of Electronic Publication: 2024 Sep 18.
DOI: 10.1038/s41586-024-07960-6
Abstrakt: Persistent colonization and outgrowth of potentially pathogenic organisms in the intestine can result from long-term antibiotic use or inflammatory conditions, and may perpetuate dysregulated immunity and tissue damage 1,2 . Gram-negative Enterobacteriaceae gut pathobionts are particularly recalcitrant to conventional antibiotic treatment 3,4 , although an emerging body of evidence suggests that manipulation of the commensal microbiota may be a practical alternative therapeutic strategy 5-7 . Here we isolated and down-selected commensal bacterial consortia from stool samples from healthy humans that could strongly and specifically suppress intestinal Enterobacteriaceae. One of the elaborated consortia, comprising 18 commensal strains, effectively controlled ecological niches by regulating gluconate availability, thereby re-establishing colonization resistance and alleviating Klebsiella- and Escherichia-driven intestinal inflammation in mice. Harnessing these activities in the form of live bacterial therapies may represent a promising solution to combat the growing threat of proinflammatory, antimicrobial-resistant Enterobacteriaceae infection.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: